

REVIEW

Open Access



# DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits

Michael Razavi<sup>1†</sup>, Ying-Ying Wei<sup>2†</sup>, Xiao-Quan Rao<sup>3\*</sup> and Ji-Xin Zhong<sup>2,4\*</sup> 

## Abstract

Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors are commonly used treatments for patients with type 2 diabetes mellitus (T2DM). Both anti-diabetic treatments function by playing key modulatory roles in the incretin system. Though these drugs have been deemed effective in treating T2DM, the Food and Drug Administration (FDA) and some members of the scientific community have questioned the safety of these therapeutics relative to important cardiovascular endpoints. As a result, since 2008, the FDA has required all new drugs for glycemic control in T2DM patients to demonstrate cardiovascular safety. The present review article strives to assess the safety and benefits of incretin-based therapy, a new class of antidiabetic drug, on the health of patient cardiovascular systems. In the process, this review will also provide a physiological overview of the incretin system and how key components function in T2DM.

**Keywords:** Glucagon-like peptide-1 receptor agonists, Dipeptidyl peptidase-4 inhibitors, Type 2 diabetes mellitus, Cardiovascular outcome

## Background

Type 2 diabetes mellitus (T2DM), a common metabolic disorder characterized by insulin resistance and inadequate insulin secretion by pancreatic  $\beta$  cells, has become a growing cause of morbidity and mortality worldwide. The mortality risk associated with T2DM is only secondary to an increase in an individual's risk of acquiring other disease states that are both vascular and nonvascular in origin [1]. Modifiable risk factors, such as diet and exercise, are important targets for intervention in the management of T2DM [2, 3]. However, for many patients, lifestyle modification alone is not adequate to

prevent further disease progression and new disease onset. Several trials, such as the United Kingdom Prospective Diabetes Study (UKPDS) and Action in Diabetes and Vascular Disease: Preterax and Diamicon MR Controlled Evaluation (ADVANCE), have demonstrated that appropriate control of blood glucose is beneficial for the reduction of long-term cardiovascular complications [4, 5]. Although diabetes is widely accepted as one of the major risk factors for cardiovascular disease, the cardiovascular safety of antidiabetic drugs has been questioned due to the finding that intensive glycemic control by antidiabetic medications may result in an unexpected increase in cardiovascular death under certain circumstances [6]. Also, the adverse cardiovascular safety in clinical trials before 2008 was evaluated based on populations that were not necessarily at high risk of cardiovascular disease and the follow-up duration was relatively short (usually less than 12 months). Therefore, the Food and Drug Administration (FDA) released a guidance requiring all new drugs for glycemic control in T2DM patients to demonstrate cardiovascular safety, a policy that was continued and further emphasized in the 2020

<sup>†</sup>Michael Razavi and Ying-Ying Wei contributed equally to this work

\*Correspondence: xqrao@tjh.tjmu.edu.cn; zhongjixin620@163.com

<sup>2</sup> Department of Rheumatology and Immunology, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, 1095 Jiefang Ave, Wuhan 430032, China

<sup>3</sup> Department of Cardiovascular Medicine, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, 1095 Jiefang Ave, Wuhan 430032, China

Full list of author information is available at the end of the article



FDA Guidance for Diabetes Drug Development [7, 8]. Pharmacological treatment modalities such as glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors have become increasingly accepted as viable antidiabetic treatment options due to their safety and favorable cardiovascular profiles [9, 10]. There has been a rapid increase in information from large-scale clinical trials assessing the cardiovascular safety and efficacy of incretin-based therapies since 2008. Therefore, an updated critical review of the cardiovascular actions of these therapies, especially information from recently completed trials is needed. The aim of this review was to summarize the recent updates from both clinical trials and preclinical experiments on the impact of GLP-1 receptor agonists (GLP-1RAs) and DPP-4 inhibitors (DPP-4i) on cardiovascular outcomes.

## Molecular bases of incretin system

### Synthesis and distribution of GLP-1

GLP-1, GLP-2, and glucose-dependent insulinotropic polypeptide (GIP) are the predominant gut-derived incretin hormones that lead to postprandial insulin secretion in a glucose-dependent fashion. GLP-1 was originally identified as a 37 amino acid (GLP-1<sub>1-37</sub>) long peptide. However, subsequent studies identified that biologically active GLP-1 is cleaved to contain only 31 amino acids (GLP-1<sub>7-37</sub>). It is also known that there is an isoform of GLP-1, which is one amino acid shorter in both the full length (GLP-1<sub>1-36</sub>) and its active form (GLP-1<sub>7-36</sub>). The biologically active forms of GLP-1 are rapidly degraded by DPP-4, resulting in the production of inactive forms of GLP-1 (GLP-1<sub>9-37</sub> and GLP-1<sub>9-36</sub>) [11].

GLP-1 is primarily produced by enteroendocrine L-cells that are dispersed throughout the small and large intestines. Yet, GLP-1 is mainly localized to the distal small bowel and colon and is released following nutrient intake [12, 13] and it has been shown that M1 and M2 muscarinic receptors may also be involved in the regulation of GLP-1 release [14].

### Molecular structure of DPP-4

DPP-4 has two domains and two subdomains:  $\alpha/\beta$  hydrolase domain (Gln508-Pro766),  $\beta$ -propeller domain (Arg54-Asn497), receptor binding subdomain, and a core subdomain [15]. DPP-4 was first identified as CD26, and is a 110 kD protein that can be found on the cell surface as a monomer, homodimer, or homotetramer. The homodimer form of DPP-4 is the main catalytically active form. The proteolytically active DPP-4 homodimer is found in two forms: a single-pass type II integral transmembrane protein and a soluble protein stripped of any membrane spanning regions or intracellular regions [16]. DPP-4 carries out its exopeptidase activity by cleaving proteins or

peptides after encountering a proline or alanine in the second position from the N-terminal end of the amino acid chain. Residues 630, 708, and 740 form the catalytic triad and are indispensable for its catalytic activity. Other functionally crucial residues are 294 and 340–343 within the cysteine-rich domain, which function as adenosine deaminase (ADA) binding domains [16]. Therefore, the functional domains responsible for currently discovered function of DPP-4 are all located in the extracellular portion and the functions of intracellular domain of DPP-4 remain elusive. The structures of DPP-4 and GLP-1 are illustrated in Fig. 1.


## Function and regulation— incretin axis

### GLP-1 and its receptor

GLP-1 secretion, in response to nutrient intake, leads to the release of insulin through the GLP-1 receptor (GLP-1R) and together with other incretin hormones accounts for 50–70% of total post-prandial insulin release [17].

The GLP-1R is a G-protein coupled receptor that has wide tissue expression, including in the brain, the wall of the portal vein near the hilus of the liver, and arteries and arterioles from various organs (kidney, heart, pancreas, and intestine) [18]. The expression of GLP-1 has been seen to spike following gastric bypass surgery and this increase in GLP-1 levels is thought to play a role in appetite suppression and is responsible for postsurgical weight loss and improvements in glucose metabolism [19]. Additionally, agonists of GLP-1R have been associated with reduced fasting very low-density lipoprotein (VLDL), which was shown to be weight-independent [20, 21]. A recent large-scale clinical trial has confirmed that tirzepatide, a dual GIP and GLP-1RAs, resulted in a weight loss of up to 20.9% in adults with body fat mass of 30 or more after 72-week follow-up [22].

Outside of these functions, GLP receptors are also expressed in the human retina and are thought to be involved in the prevention of retinal neurodegeneration, an early event in diabetic retinopathy [23]. Additionally, both GLP-1 and GIP play a role in cardiovascular disease, as agonists of GLP-1 have been shown to reduce platelet activation, thus supporting a protective effect of GLP-1 against microvascular thrombosis [24]. Furthermore, GLP-1 plays a protective role in cardiac microvasculature in diabetes by preventing apoptosis, oxidative stress, and microvascular dysfunction. GLP-1 is thought to mediate this through inhibiting Rho GTPase in the cyclic adenosine 3',5'-monophosphate (cAMP)/protein kinase A (PKA) pathway [25]. Although the effects of GLP-1 are mostly consistent with an anti-atherogenic function, GIP may have opposing effects that may be viewed as pro-atherogenic. For example, in short term infusion studies in



**Fig. 1** Molecular basis of incretin axis: DPP-4 proteins consist of a short intracellular domain (6 amino acids), a transmembrane domain, and a large extracellular domain. The extracellular domain is responsible for the enzymatic cleavage of the substrates and binding to its ligands including fibronectin and ADA. DPP-4 inactivates GLP-1 by removing N-terminal dipeptide His7Ala8 from active form of GLP-1, which results in the loss of its affinity to GLP-1R. GLP-1R is a G-protein coupled receptor and its binding with active GLP-1 activates PI3K and PKA pathway by increasing intracellular cAMP concentration. DPP-4 dipeptidyl peptidase-4, sDPP-4 soluble DPP-4, AA amino acid, ADA adenosine deaminase, GLP-1 glucagon-like peptide-1, GLP-1R glucagon-like peptide-1 receptor, cAMP cyclic adenosine monophosphate, PKA protein kinase A, PI3K phosphoinositide 3-kinase

humans, GIP increases the level of osteopontin, which is considered to be a pro-atherogenic cytokine [26].

Despite the wide presence of GLP-1R throughout bodily tissues, it is predominantly found in islet  $\beta$ -cells and postprandial insulin release from these cells is dependent upon the ability of GLP-1 to interact with GLP-1R [27]. This process follows a known pathway in which

the interaction between GLP-1 and its receptor, initiates Gas-protein coupling. This leads to the immediate release of cAMP and the eventual downstream release of calcium and  $\beta$ -arrestin. The downstream release of these three factors, in response to GLP-1R activation, leads to glucose-dependent insulin release. Studies in which GLP-1R was deleted or knocked out in murine models resulted

in impaired glucose-dependent insulin release. Thus, GLP-1R is thought to be a key component of the incretin effect—insulin secretion in response to oral glucose intake [27].

### Regulation of incretin system

Current literature has shown that somatostatin can lower levels of GLP-1 released during the fasting state, suggesting the existence of basal levels of GLP [28]. There is an approximately threefold increase in GLP from basal levels, observed in response to oral intake of glucose [28]. To this end, GLP-1 is not produced in response to intravenous glucose and instead, the amount of GLP-1 released is relative to the size of a meal and is correlated to the rate of gastric emptying [29]. It has also been shown that the response of GLP-1 to meals is unaffected by small intestinal resections which can interrupt intramural reflux pathways [30].

Following their release into the blood stream, incretin peptides are rapidly inactivated by enzymatic cleavage. DPP-4 is a key modulator of the incretin system, and functions to catalytically inactivate GLP-1 and GIP. Specifically, GLP-1 and GIP are cleaved into two biologically inactive forms, GLP-1<sub>9–37</sub> (or GLP-1<sub>9–36</sub>) and GIP<sub>3–42</sub>. Rapid inactivation of these incretin hormones by DPP-4 leads to an insufficient release of insulin following oral glucose intake [31] and many of the physiological signs of T2DM, such as deteriorating glycemic control, are secondary to incretin inactivation by DPP-4. DPP-4 expression is positively correlated with glycated hemoglobin (HbA1c), adipocyte size, inflammation, and visceral adipose tissue [17, 32].

Overall, regulation of DPP-4 remains nebulous. However, previous studies have found that DPP-4 can be regulated by inflammatory factors such as signal transducer and activator of transcription 1 $\alpha$  (STAT1 $\alpha$ ), hepatocyte nuclear factor-1 $\alpha$  (HNF-1 $\alpha$ ), interleukin-12 (IL-12), and tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ) [33–35]. Specifically, STAT1 $\alpha$  is thought to play a role in transcriptional regulation as the promoter region of DPP-4 contains an interferon-gamma-activated sequence (GAS), which is an activated STAT1 $\alpha$  binding site. STAT1 $\alpha$  becomes active in response to retinoic acid and interferon  $\alpha$ ,  $\beta$ , and  $\gamma$ , leading to the binding of STAT1 $\alpha$  to GAS in the DPP-4 promoter. This mechanism of promoter binding leads to increased DPP-4 transcription [33]. Similarly, T-helper cell 17 skewing condition (TGF- $\beta$ , IL-23, IL-6, IL-1 $\beta$ , and IL-21) also results in increased DPP-4 expression [34]. Furthermore, IL-12 is thought to promote DPP-4 translation, whereas TNF- $\alpha$  is thought to decrease its expression [34, 35]. Our recent work demonstrated that oxidized low-density lipoprotein (LDL) upregulates


DPP-4 expression on macrophages via activation of Toll-like receptor 4 (TLR4)/TIR-domain-containing adapter-inducing interferon- $\beta$  (TRIF) and CD36 pathways [36]. Decreased DPP-4 or CD26 expression is also seen in cases where CD9 is deleted and in murine models of hyperoxygenation [35]. Related to relative oxygen concentration, DPP-4 is thought to be released [potentially mediated by matrix metalloproteases (MMPs)] in human smooth muscle cells under hypoxic conditions. To this end, HIF-1 $\alpha$  and HNFs have been shown to target DPP-4 expression [35]. Hypoxic conditions can also lead to a phenomenon known as DPP-4 shedding whereby transmembrane DPP-4 is cleaved from the membrane and released into the circulation in a soluble form. Hypoxia-induced shedding is thought to occur due to an intricate interaction between various MMPs [37].

In summary, GLP-1 and its analogues appear to exert multiple important actions in brain, liver, muscle and fat in addition to its main action of stimulating insulin secretion. However, the rapid inactivation of GLP-1 by DPP-4 *in vivo* limits its application in clinic. By preserving GLP-1, DPP-4i enhances GLP-1-induced activities in these tissues (Fig. 2).

### Effects on glycemic control

#### Blood glucose lowering effect of GLP-1RAs

As previously noted, DPP-4 rapidly cleaves and inactivates GLP-1, resulting in its very short half-life (2–3 min). While DPP-4 expression is significantly increased in patients with obesity and T2DM, the incretin effect is markedly impaired. Early studies revealed that GLP-1 injections improved postprandial insulin release, lowered fasting glucose and HbA1c levels, and led to modest weight loss [38]. Exendin-4 (exenatide), a GLP-1 peptide encoded by lizard genes that is resistant to DPP-4-mediated catalytic degradation, received FDA approval in 2005 and became the first GLP-1RA available for public use. Between 2005 and 2021, the following GLP-1 agonists were also approved by the FDA for parenteral use: liraglutide, albiglutide, lixisenatide, dulaglutide, and semaglutide. Lixisenatide was also approved during that timeframe, for use in Europe [31]. The individual agents differ in their unique pharmacology such as half-life and degree of structural homology to GLP-1 [39]. As a class, however, these agents work similarly where they mimic the structure of GLP-1 *in vivo*, and thus, can bind the GLP-1R, but are not subject to degradation by DPP-4. This degradation by DPP-4 is evaded because most GLP-1 analogues contain an amino acid substitution at the N-terminal end. For example, exendin-based GLP-1 analogues have an alanine to glutamic acid substitution in the second position [40].



**Fig. 2** Incretin axis and incretin-based therapies: GLP-1 is produced by the enteroendocrine L-cells in response to meal ingestion. The active form of GLP-1 is rapidly inactivated by DPP-4. GLP-1 acts on pancreas, liver, gastrointestinal tract, adipose tissue, cardiovascular system, and brain to exert a variety of functions. The rapid inactivation by DPP-4 in vivo limits the application of GLP-1 in clinic. The development of DPP-4 resistant analogues (GLP-1RAs) and DPP-4i overcame the instability shortcoming of GLP-1 and became an important class of glycemic lowering drugs that are safe or beneficial to cardiovascular disease. GLP-1RAs reduce multiple cardiovascular risks such as hypertension, hyperglycemia, dyslipidemia, overweight, and insulin resistance via various mechanisms. DPP-4 dipeptidyl peptidase-4, DPP-4i DPP-4 inhibitors, GLP-1 glucagon-like peptide-1, ApoB48 apolipoprotein B48, VLDL very low-density lipoprotein, LDL low-density lipoprotein

Overall, GLP-1RAs have been shown to be effective in managing T2DM and have helped patients reduce HbA1c by 2% over the course of 18 months to reach levels below 7% [41]. Likewise, they can increase insulin secretion by improving beta-cell survival and suppressing glucagon secretion by improving alpha-cell health and glucose sensing ability. Additionally, GLP-1RAs were able to address the pathophysiology of T2DM through an indirect mechanism also. Slowed gastric emptying, weight loss, and favorable results on lipid parameters have all been associated with GLP-1RAs use [40]. The overall mechanisms by which GLP-1RAs carry out their cardiometabolic effects are still unclear, however recent studies suggest that this process may be mediated by reduction of inflammation and epicardial adipose tissue [42, 43].

**Blood glucose lowering effect of DPP-4i**

DPP-4i are oral anti-diabetic drugs that function by blocking incretin degradation caused by DPP-4, as outlined earlier in this review. Blocking the catalytic breakdown of GLP-1 and GIP, allows for postprandial insulin release [44]. Murine-based studies have shown that DPP-4 inhibition directly results in increased GLP-1 secretion and improves both overall insulin secretion and

glucose tolerance. To this end, DPP-4 knockout mice also showed similar findings, indicating that DPP-4 inhibition is an effective mechanism for treating T2DM [45].

The FDA approved sitagliptin, the first DPP-4i on the market, in 2006 and shortly after, numerous additional DPP-4i received market clearance. The FDA approved saxagliptin, linagliptin, and alogliptin, and the European Union and Japan approved vildagliptin, anagliptin, teneligliptin, trelagliptin, and omarigliptin. Gemigliptin and evogliptin were soon approved in Korea, and gosogliptin was approved in Russia. These inhibitors differ based on which of the two DPP-4 structural classes they belong to (non-peptidomimetics or dipeptide structural mimics), their metabolism (liver vs. kidney routes), their excretion, their elimination half-life, their target selectivity, and their effective dosage [46].

Collective data from major clinical trials have shown that treatment with a DPP-4i improves glycemic control by increasing insulin secretion from islet cells, lowering levels of HbA1c, reducing adipocyte size, and suppressing inflammation [47–51]. Unlike GLP-1RAs, DPP-4i have no effect on gastric emptying or weight loss. In addition to improved glycemic control, Nakamura et al. [52] showed that a 12-month treatment with sitagliptin

significantly decreased systolic [ $(-7.0 \pm 18.9)$  mmHg] and diastolic [ $(-5.1 \pm 11.7)$  mmHg] blood pressure in patients with both T2DM and cardiovascular risk factors. A slight reduction in blood pressure has also been observed in SUSTAIN-6 and LEADER trials [53, 54]. However, this effect was not seen in other major cardiovascular outcome trials (CVOTs) and their blood pressure lowering effect remains controversial, which will be further discussed below.

## CVOTs

In response to FDA guidelines requiring the assessment of anti-diabetic therapeutics in relation to cardiovascular risk, several CVOTs have been performed. These outcome trials aimed to determine cardiovascular safety and thus most of them were designed to show non-inferiority of the drug against placebo. To rule out inferiority, the FDA required CVOTs to show an upper boundary risk ratio of 1.3 (post approval), utilizing a two-sided 95% confidence interval (CI), for major adverse cardiovascular events (MACE) [55]. In this section, we reviewed all major CVOTs with published results by searching the MEDLINE and EMBASE databases using the following terms: 1) glucagon-like peptide-1 agonists OR GLP-1RAs; 2) glucagon like peptide OR GLP-1; 3) exenatide OR lixisenatide OR liraglutide OR semaglutide OR albiglutide OR dulaglutide OR efpeglenatide; 4) randomized controlled trial; 5) cardiovascular outcome OR cardiovascular safety OR cardiovascular events; 6) DPP4 OR DPP-4 OR DPP-IV; 7) dipeptidyl peptidase-4; and 8) alogliptin OR saxagliptin OR sitagliptin OR linagliptin OR vildagliptin. The search strategy [(1 OR 2 OR 3) AND 4 AND 5] was used for CVOTs with GLP-1RAs and [(6 OR 7 OR 8) AND 4 AND 5] was used for CVOTs with DPP-4i. Trials with less than 4000 patient-years of exposure to the drug were excluded according to the updated FDA Guidance for Diabetes Drug Development released in 2020 [8]. The following CVOTs, relative to DPP-4i and GLP-1RAs, have been identified and included in this review: EXAMINE, SAVOR-TIMI53, TECOS, CARMELINA, CAROLINA, ELIXA, SUSTAIN 6, EXSCCEL, HARMONY, LEADER, PIONEER 6, REWIND, and AMPLITUDE-O [47–49, 53, 54, 56–63]. All trials revealed cardiovascular safety by establishing non-inferiority. Interestingly, the superiority analyses showed heterogeneous results among these trials. One important reason for this phenomenon may be the heterogeneity in subject disease conditions, follow-up durations, and kinetics of drugs. In the following sections, we will review these CVOTs on incretin-based therapies in detail.

## Effects on classic cardiovascular risk factors

### CVOTs on GLP-1RAs

Data from the major CVOTs ELIXA, SUSTAIN-6, EXSCCEL, HARMONY, PIONEER 6, LEADER, REWIND, and AMPLITUDE-O [53, 54, 56, 59–63] support the overall safety of GLP-1RAs relative to major cardiovascular outcomes. Specifically, the ELIXA (lixisenatide) trial studied patients with T2DM who had recent acute coronary syndrome and found that the addition of lixisenatide to conventional therapy did not result in a significant difference in cardiovascular endpoints relative to placebo (Table 1) [56]. SUSTAIN-6 (semaglutide) [53], PIONEER 6 (semaglutide) [61], and LEADER (liraglutide) [54] looked at similar patient populations (over 50 years old with established cardiovascular disease) and found that GLP-1RAs produce a cardiovascular protective function relative to primary endpoints (Table 1). Both SUSTAIN-6 and LEADER showed a statistically significant decrease in MACE [53, 54]. Although PIONEER 6 only showed an insignificant reduction of MACE, subcategory analysis demonstrated significant improvement in all-cause mortality [1.4% vs. 2.8%, hazard ratio (*HR*) = 0.51, 95% CI 0.31–0.84] and cardiovascular mortality (0.9% vs. 1.9%, *HR* = 0.49, 95% CI 0.27–0.92) [61]. The HARMONY trial studied T2DM patients, 40 years and older, with established cardiovascular disease and reported that albiglutide reduced the primary composite outcome. The incidence rates of the primary composite outcome were 4.6 and 5.9 events per 100 person-years for albiglutide vs. placebo respectively (*HR* = 0.78, 95% CI 0.68–0.90, *P* < 0.0001 for non-inferiority; *P* = 0.0006 for superiority) [60]. Furthermore, Ferdinand et al. [64] found that dulaglutide, a long-lasting form of GLP-1RA administered once weekly, is also safe and does not increase the risk of major cardiovascular events in patients with T2DM. The recently completed large-scale REWIND trial randomized 9901 patients with T2DM to either placebo or dulaglutide. Unlike its predecessors, the REWIND trial was not aimed at uncovering cardiovascular safety of GLP-1RAs. Rather, it focused on specifically determining the cardiovascular superiority of dulaglutide relative to cardiovascular endpoints. During a median follow-up of 5.4 (IQR 5.1–5.9) years, patients with a 1.5 mg/week subcutaneous injection of dulaglutide showed a lower incidence rate of the primary composite outcome including non-fatal myocardial infarction, non-fatal stroke, or death from cardiovascular causes (*HR* = 0.88, 95% CI 0.79–0.99, *P* = 0.026) [62]. Additionally, compared to glimepiride, a commonly used sulfonylurea, exenatide was able to significantly reduce cardiovascular risk factors such as body mass index, blood pressure, and high-density lipoprotein (HDL). These results suggest that GLP-1RAs may be preferred to sulfonylureas as an

**Table 1** Summary of main CVOTs for GLP-1RAs

Characteristic	ELIXA (2015) [56]	SUSTAIN-6 (2016) [53]	LEADER (2016) [54]	EXSCEL (2017) [59]	HARMONY (2018) [60]	PIONEER 6 (2019) [61]	REWIND (2019) [62]	AMPLITUDE-O (2021) [63]
Drug	Lixisenatide	Semaglutide	Liraglutide	Exenatide	Albiglutide	Semaglutide	Dulaglutide	Efglenatide
Control	Placebo	Placebo	Placebo	Placebo	Placebo	Placebo	Placebo	Placebo
Median follow-up (years)	2.1	2.1	3.5	3.2	1.6	1.3	5.4	1.81
Inclusion criteria	T2DM and acute coronary events within the past 180 d	≥ 50 years of age with established CVD, HF (class I or II), CKD (stage 3+), or ≥ 60 with cardiovascular risk factor	≥ 50 years of age with established CVD, HF (class I or II), CKD (stage 3+), or ≥ 60 with cardiovascular risk factor	T2DM on 0–3 oral or insulin antidiabetic drugs; HbA1c 6.5–10.0%	≥ 40 years of age with T2DM; HbA1c > 7.0%; established CVD	≥ 50 years; T2DM with established CVD; or ≥ 60 with cardiovascular risk factor	≥ 50 years; T2DM with HbA1c ≤ 9.5%; two or less oral glucose-lowering drugs	T2DM with history of CVD or eGFR 25.0 to 59.9 ml/(min·1.73 m <sup>2</sup> )
Exclusion criteria	< 30 years of age, PCI within past 15 d, CABG for the qualifying event, planned revascularization, eGFR < 30 ml/(min·1.73 m <sup>2</sup> ), HbA1c < 5.5% or > 11.0%	Treatment with DPP-4i, GLP-1R, or insulin other than basal within 30 d; premixed insulin treatment within 90 d; acute coronary or cerebrovascular event within 90 d; planned coronary intervention	T2DM; use of GLP-1RAs; history of gastroparesis; pancreatitis; pregnancy; eGFR < 30 ml/(min·1.73 m <sup>2</sup> ); planned revascularization	T1DM; use of GLP-1RAs; history of gastroparesis; pancreatitis; pregnancy; eGFR < 30 ml/(min·1.73 m <sup>2</sup> ); planned revascularization	eGFR < 30 ml/(min·1.73 m <sup>2</sup> ); use of GLP-1RAs; severe gastroparesis; history of pancreatitis; pancreatic tumors; mediastinal carcinoma of the thyroid; pregnancy, breastfeeding	Use of DPP-4i, GLP-1R; malignant neoplasms; pancreatitis; HF class IV; planned revascularisation; eGFR < 30 ml/(min·1.73 m <sup>2</sup> )	eGFR < 15 ml/(min·1.73 m <sup>2</sup> ); cancer; severe hypoglycemia; history of life expectancy < 1 year; coronary or cerebrovascular event within 2 months; planned revascularization	History of GI disease, pancreatitis; hypertension; personal or family history of medullary thyroid cancer; planned coronary procedure; use of DPP-4i, GLP-1R; retinopathy or maculopathy
Results of primary endpoint (vs. placebo)	Non-inferiority; HR = 1.02 (95% CI 0.89–1.17)	6.6% vs. 8.9%; HR = 0.74 (95% CI 0.58–0.95); P < 0.001 for non-inferiority; P = 0.02 for superiority	HR = 0.87 (95% CI 0.78–0.97); P < 0.001 for non-inferiority; P = 0.01 for superiority	11.4% vs. 12.2%; HR = 0.91 (95% CI 0.83–1.00); P = 0.06 for superiority	7% vs. 9%; HR = 0.78 (95% CI 0.68–0.90); P < 0.0001 for non-inferiority; P = 0.0006 for superiority	3.8% vs. 4.8%; HR = 0.79 (95% CI 0.57–1.11); P = 0.17*	12.0% vs. 13.4%; HR = 0.88 (95% CI 0.79–0.99); P = 0.026 for superiority	7.0% vs. 9.2%; HR = 0.73 (95% CI 0.58–0.92); P < 0.001 for non-inferiority; P = 0.007 for superiority
HF	HR = 0.96 (95% CI 0.75–1.23)	HR = 1.11 (95% CI 0.77–1.61)	4.7% vs. 5.3%; HR = 0.87 (95% CI 0.73–1.05)	HR = 0.94 (95% CI 0.78–1.13)	HR = 0.85 (95% CI 0.70–1.04)	1.3% vs. 1.5%; HR = 0.86 (95% CI 0.48–1.55)	HR = 0.93 (95% CI 0.77–1.12)	HR = 0.61 (95% CI 0.38–0.98)
Myocardial infarction	HR = 1.03 (95% CI 0.87–1.22)	HR = 0.74 (95% CI 0.51–1.08)	6.3% vs. 7.3%; HR = 0.86 (95% CI 0.73–1.00)	HR = 0.97 (95% CI 0.85–1.10)	HR = 0.75 (95% CI 0.61–0.90)	HR = 1.18 (95% CI 0.73–1.90)	4.1% vs. 4.3%; P = 0.65	HR = 0.75 (95% CI 0.54–1.05)

\*Significant improvement in all-cause mortality (1.4% vs. 2.8%, HR = 0.51; 95% CI 0.31–0.84), cardiovascular mortality (0.9% vs. 1.9%, HR = 0.49; 95% CI 0.27–0.92), CVOI's cardiovascular outcome trials, T2DM type 2 diabetes mellitus, CVD cardiovascular disease, HF heart failure, CKD chronic kidney disease, HbA1c glycated hemoglobin, eGFR estimated glomerular filtration rate, PCI percutaneous coronary intervention, CABG coronary artery bypass graft, GLP-1R GLP-1 receptor, T1DM type 1 diabetes mellitus, GLP-1RAs glucagon-like peptide-1 receptor agonists, DPP-4i DPP-4 inhibitor, HR hazard ratio, CI confidence interval

add-on therapy [65]. Efpeglenatide, an exendin 4-based molecule, also showed a significant reduction in major adverse cardiovascular events (7.0% vs. 9.2%,  $HR=0.73$ , 95%CI 0.58–0.92,  $P<0.001$  for non-inferiority;  $P=0.007$  for superiority) in T2DM patients with a history of cardiovascular disease or current kidney disease in a recently completed trial (AMPLITUDE-O) [63]. This result suggested that the long-acting form, unlike the short-acting forms (lixisenatide and exenatide), of exendin-4-based GLP-1RAs improved cardiovascular outcomes. This also supports the finding that the cardiovascular benefits are not restricted to those agents structurally similar to human GLP-1 but are more likely a class effect that is seen in all GLP-1RAs. As a class, GLP-1RAs were also seen to reduce all-cause mortality by 11% compared to placebo [54]. Specific to cardiovascular-related death, ELIXA and SUSTAIN-6 trials showed similar performance relative to the placebo [ $HR=0.98$  (95% CI 0.78–1.22) and  $HR=0.98$  (95% CI 0.65–1.48), respectively]. Conversely, the use of liraglutide in the LEADER trial led to a 22% reduction in cardiovascular deaths [53, 54, 56].

Except for ELIXA and EXSCEL [56, 59], all other major CVOTs point towards cardiovascular benefits of GLP-1RAs [53, 54, 61, 63, 66–68]. Recent meta-analyses of the major CVOTs for GLP-1RAs have also demonstrated an overall protective effect of GLP-1RAs on cardiovascular events [69, 70]. Evidently, the differences amongst the results point towards in-class heterogeneity. It is noteworthy that the study populations were highly specific in these trials (refer to inclusion and exclusion criteria sections of Table 1) and most trials recruited patients with established cardiovascular disease or having high risk of cardiovascular disease. Therefore, the heterogeneities in cardiovascular medication, baseline characteristics, study population, and study design should be taken into consideration when comparing the results among these trials. Particularly, the background anti-diabetic agents, lipid-lowering drugs, antiaggregants, and antihypertensives may affect cardiovascular events. In addition to the different study populations and study design in these trials, one potential reason for this heterogeneity in cardiovascular benefit is the structural differences among the GLP-1RAs used in these trials. Lixisenatide and exenatide used in ELIXA and EXSCEL trials are short-acting GLP-1RAs that are structurally similar to exendin-4, a peptide found in the saliva of the Gila monster *Heterodermis suspectum*. The GLP-1RAs used in the other trials, including liraglutide, semaglutide, dulaglutide, and albiglutide, are all analogous to human GLP-1. It has recently been reported that human GLP-1 analogues were more effective in reducing the occurrence of major adverse cardiovascular events, myocardial infarctions, and hospitalizations due to cardiovascular causes when compared

to exendin-based GLP-1RAs [71]. It should also be noted that ELIXA and REWIND were the only two trials where average baseline HbA1c level was lower than 8%. In addition, the follow-up duration of ELIXA was also relatively short (2.1 years), especially when compared with the follow-up duration of 5.4 years in the REWIND trial [60, 62].

GLP-1RAs have been shown to reduce blood pressure, although the exact mechanism is unknown. It is believed that GLP-1RAs induce vasodilation through action of the proximal tubular cells and stimulating urinary sodium excretion [68, 72]. GLP-1 injections were also shown to improve myocardial tolerance to stress induced ischemia at peak activity and 30 min post-activity [73]. Gaspari et al. [74] used an apolipoprotein-E deficient (ApoE<sup>-/-</sup>) mouse model to show the beneficial effects of liraglutide as they relate to atherosclerotic vascular disease. The beneficial effects observed in those patients with early onset, low atherosclerotic burden include an improvement in plaque stability score in the brachiocephalic artery, attenuation of lipid deposits in the aorta, and reduction of weight gain. For high burden atherosclerosis, there was an observed attenuation of endothelial dysfunction in the liraglutide treatment group. GLP-1RAs, specifically liraglutide, have also been evaluated for their effects on cardiovascular biomarkers. The specific biomarkers focused on were adiponectin, leptin, IL-6, TNF- $\alpha$ , plasminogen activator inhibitor-1 (PAI-1), brain natriuretic peptide (BNP), and high-sensitivity C-reactive protein (hs-CRP). Increased levels of PAI-1 and BNP were found post-14-week treatment with liraglutide [66].

#### CVOTs on DPP-4i

Data from TECOS, EXAMINE, SAVOR-TIMI53, CARMELINA, and CAROLINA showed that DPP-4i are non-inferior to the placebo or glimepiride relative to primary cardiovascular endpoints [17, 48, 49, 57, 58]. Unlike GLP-1RAs, none of the DPP-4i tested displayed superiority over the placebo in relation to the primary endpoint and the detailed results of these three trials are described in Table 2. It is important to note that these clinical trials were designed as non-inferiority studies. Thus, supporting the cardiovascular safety of these drugs and not necessarily their observed benefits. To make firmer conclusions, additional clinical trials designed around revealing cardiovascular benefits should be conducted. Despite the superior cardiorenal benefits of sodium/glucose cotransporter-2 inhibitors (SGLT-2i) and GLP-1RAs [75, 76], DPP-4i remained a common choice among these three classes of anti-diabetic agents, with more patients using DPP-4i than the other two [77]. In-class differences were noticed especially related to heart failure (HF) and are discussed later in this manuscript. Among these



**Table 2** Summary of main CVOTs for DPP-4i

Characteristic	EXAMINE (2013) [48]	SAVOR-TIMI53 (2015) [49]	TECOS (2015) [47]	CARMELINA (2019) [57]	CAROLINA (2019) [58]
Drug	Allogliptin Placebo	Saxagliptin Placebo	Sitagliptin Placebo	Linagliptin Placebo	Linagliptin Glimepiride
Comparative agent	1.5	2.1	3	2.2	6.3
Median follow-up period (years)					
Inclusion criteria	≥ 18 years with T2DM who are receiving mono or combination therapy (excluding GLP-1RAs or DPP-4i); HbA1c levels between 6.5 and 11.0%; History of ACS within 15–90 days of screening	T2DM with HbA1c between 6.5 and 12.0% and an established cardiovascular disease or multiple vascular risk factors	≥ 50 years of age with T2DM; HbA1c 6.5 and 8.0% when treated with OAD or insulin; established cardiovascular disease	T2DM with HbA1c of 6.5–10.0%; high cardiovascular risk; high renal risk: eGFR 45–75 ml/(min·1.73 m <sup>2</sup> ) and UACR ≥ 200 mg/g, or eGFR 15–45 ml/(min·1.73 m <sup>2</sup> )	Age 40–85 years; T2DM with increased cardiovascular risk or established CVD; HbA1c of 6.5–8.5%; BMI ≤ 45 kg/m <sup>2</sup>
Exclusion criteria	T1DM; currently on GLP-1RAs; taken DPP-4i for > 14 d or within past 3 months; unstable cardiovascular disorder; dialysis; severe immunodeficiency	Treatment with incretins in the past 6 months; dialysis; prior renal transplant; or serum creatinine higher than 6.0 mg per deciliter	Prior treatment with GLP-1RAs, DPP-4i; thiazolidinedione within the last 3 months; two or more hypoglycemia episodes in the past 12 months; eGFR < 30 ml/(min·1.73 m <sup>2</sup> )	T1DM; prior use of GLP-1RAs or DPP-4i; eGFR < 15 ml/(min·1.73 m <sup>2</sup> ) or requiring maintenance dialysis; liver disease; bariatric surgery; nursing or pregnant women	T1DM; insulin therapy; prior use of DPP-4i, GLP-1RAs, or thiazolidinedione; uncontrolled hyperglycemia; liver disease; HF class III or IV
Results of primary endpoint (vs. placebo/control)	HR = 0.96 (upper boundary of the one-sided repeated CI 1.16; P = 0.32 for superiority; P < 0.001 for non-inferiority)	HR = 1.00 (95% CI 0.89–1.12; P = 0.99 for superiority; P < 0.001 for non-inferiority)	HR = 0.98 (95% CI 0.88–1.09; P < 0.001 for non-inferiority; intention-to-treat analysis: 0.98; 95% CI 0.89–1.08; P = 0.65 for superiority)	HR = 1.02 (95% CI 0.89–1.17); P < 0.001 for non-inferiority	11.8% vs. 12.0%; HR = 0.98 (95% CI 0.84–1.14; P < 0.001 for non-inferiority; P = 0.76 for superiority)
HF hospitalization	HR = 1.07 (95% CI 0.79–1.46)	3.5% vs. 2.8%; HR = 1.27 (95% CI 1.07–1.51; P = 0.007)	3.1% vs. 3.1%; HR = 1.00 (95% CI 0.83–1.20); P = 0.98	6.0% vs. 6.5%; HR = 0.90 (95% CI 0.74–1.08); P = 0.26	HR = 1.21 (95% CI 0.92–1.59); P = 0.18
Myocardial infarction	6.5% vs. 6.9%; HR = 1.08 (95% CI 0.88–1.33)	HR = 0.95 (95% CI 0.80–1.12); P = 0.52	HR = 0.95 (95% CI 0.81–1.11); P = 0.49	HR = 0.78 (95% CI 0.36–1.72); P = 0.54*	HR = 1.03 (95% CI 0.82–1.29); P = 0.82
All-cause mortality	6.5% vs. 5.7%; HR = 0.88 (95% CI 0.71–1.09)	HR = 1.11 (95% CI 0.96–1.27); P = 0.15	HR = 1.01 (95% CI 0.90–1.14); P = 0.88	10.5% vs. 10.7%; HR = 0.98 (95% CI 0.84–1.13); P = 0.74	HR = 0.91 (95% CI 0.78–1.06); P = 0.23

\*Fatal myocardial infarction. CVOTs cardiovascular outcome trials, T2DM type 2 diabetes mellitus, GLP-1RAs GLP-1 receptor agonists, HbA1c glycated hemoglobin, ACS acute coronary syndrome, OAD oral antidiabetic drugs, eGFR estimated glomerular filtration rate, UACR urine albumin-creatinine ratio, CVD cardiovascular disease, BMI body mass index, T1DM type 1 diabetes mellitus, DPP-4i DPP-4 inhibitor, HR hazard ratio, CI confidence interval, HF heart failure

major CVOTs, the CAROLINA study compared the cardiovascular safety of linagliptin with that of glimepiride. Relative to glimepiride (sulfonylurea), DPP-4i were not associated with any increase in cardiovascular risk for patients with T2DM [58]. Although no improvement of cardiovascular outcomes was observed, linagliptin showed a better management of blood glucose with a higher rate of maintaining HbA1c below 7.0% (16.0% vs. 10.2%,  $HR=1.68$ , 95% CI 1.44–1.96) and a lower incidence of hypoglycemic adverse events (10.6% vs. 37.7%,  $HR=0.23$ , 95% CI 0.21–0.26) [58].

Outside of those major clinical trials, a nationwide retrospective study in Taiwan, China, evaluated the effects of DPP-4i in elderly patients with T2DM relative to cardiovascular outcomes. Specifically, Shih et al. [67] studied a cohort of over 400,000 T2DM patients above the age of 65 and found that DPP-4i were associated with a 21% decrease in the risk of MACEs (including myocardial infarction and ischemic stroke) with a 46% overall decrease in risk of all-cause mortality. Furthermore, in this same cohort, there were no significant differences in the rates of hospitalization for HF between the treatment and placebo groups. These findings were also found consistent across comorbidity subgroups [67].

DPP-4i have been associated with a reduction in atherosclerosis and inflammation in several studies utilizing animal models [78–80]. The effect of sitagliptin on coronary atherosclerosis was studied utilizing intravascular ultrasound (IVUS). A non-significant reduction in coronary plaque volume, decrease in liquid plaque volume, and a decrease in non-HDL cholesterol was observed in the sitagliptin group [81]. Additionally, de Boer et al. [51] found that linagliptin decreases aortic pulse wave velocity (PWV), a surrogate marker for arterial stiffness and early atherosclerosis, by an average of 0.91 m/s.

#### **Mechanisms underlying cardiovascular effects of incretin therapy**

In addition to glycemic effects, GLP-1RAs also favorably modulate multiple cardiovascular risk factors via acting on a variety of organ systems. By signaling through GLP-1R expressed in the reward and satiety areas of central nervous system, GLP-1RAs reduce caloric intake and result in 1–4 kg weight loss on average over several months. The long-term weight loss effect of GLP-1RAs has also been validated in a recent large-scale clinical trial, which reported a weight loss up to 20.9% after 72-week treatment of tirzepatide [22]. Sustained treatment with semaglutide leads to a reduction of blood pressure by 1.8 to 4.6 mmHg compared with other glucose-lowering agents or placebo [82, 83]. Modest reductions in LDL-cholesterol, total cholesterol, and triglycerides are also observed in patients receiving

GLP-1RAs when compared with other antidiabetic agents [84].

GLP-1 and its analogues have been shown to possess direct effects on improving cardiomyocyte viability, cardiac function, and vasodilation. DPP-4i and GLP-1RAs are able to enhance vasodilation by increasing nitric oxide production, promote myocyte glucose uptake, and increase coronary flow, thus providing cardioprotective effects during the acute phase of ischemic heart diseases [85–88]. Therefore, direct protection of cardiovascular system and favorable effects on multiple cardiovascular risk factors (hyperglycemia, blood pressure, dyslipidemia, body weight) observed in patients receiving GLP-1RAs may provide an explanation for the cardiovascular benefits of GLP-1RAs (Fig. 2).

#### **HF**

The prevalence of HF has become an increasing concern for patients with T2DM. Large CVOTs and other smaller studies have shown an association between the use of GLP-1RAs and DPP-4i on the relative rates of HF hospitalization.

#### **Effects of GLP-1RAs on HF**

On the whole, meta-analyses have shown that GLP-1RAs reduced the risk of developing HF ( $HR=0.62$ , 95% CI 0.31–1.02) [89]. Individual agents within this class did show some variability, however. For example, liraglutide was associated with a non-significant increased risk of HF relative to placebo [odds ratio ( $OR$ )=4.85, 95% CI 0.75–31.36] [89].

For patients with established HF and a reduced left ventricular ejection fraction (LVEF), the LIVE and FIGHT trials studied the effect of 2-year liraglutide use [90, 91]. Both studies reported almost no change in LVEF between the placebo and treatment groups (Table 3). Additionally, data was collected from ELIXA, LEADER, EXCEL, SUSTAIN-6, HARMONY, PIONEER 6, REWIND, and AMPLITUDE-O [53, 54, 56, 59–63]. All supported a non-significant difference in rates of hospitalization for HF relative to the placebo (Table 1).

However, Arturi et al. [92] studied a similar patient population and found improved LVEF after a 52-week treatment with liraglutide, and Chen et al. [93] found that in patients who had HF and a preserved LVEF, a notable increase in LVEF with a 1-week treatment of liraglutide. The patients studied by Chen et al. had an additional history of STEMI + percutaneous coronary intervention (PCI) or non-STEMI. Similar to this, in a meta-analysis study including 6 randomized controlled trials, Huang et al. [94] found that patients who were treated with GLP-1RAs after a heart attack related PCI, showed improved LVEF and reduced infarct size.

**Table 3** Trials of GLP-1RAs on HF outcomes

Characteristic	LIVE (2016) [91]	FIGHT (2016) [90]
Drug	Liraglutide Placebo	Liraglutide Placebo
Comparative agent	Placebo	Placebo
Follow-up period (weeks)	24.0	25.7
Inclusion criteria	Patients aged 30–85 years with CHF; LVEF $\leq$ 45%; functional class I–III; patients both with and without T2DM were included	HF with LVEF $\leq$ 40%; hospitalization for acute HF within last 14 d despite prior treatment; preadmission dose of 40 mg of furosemide or equivalent
Exclusion criteria	Class IV HF; MI within the last 3 months; type 1 diabetes; HbA1c > 10%; heart disease hospitalization in last 30 d; Afib with ventricular frequency above 100/min at rest; coronary revascularization within the last 3 months; obstructive hypertrophic cardiomyopathy; use of GLP-1RAs within last 30 d	Acute coronary syndrome or intervention; intolerance to GLP-1RAs; severe renal, hepatic, or pulmonary failure
Primary endpoint	Change in LVEF	Global rank score (higher values indicated better health); time to death, time to rehospitalization for HF, and time-averaged proportional change in N-terminal pro-B-type natriuretic peptide level from baseline to 180 d
Results of endpoint	Absolute increase in LVEF: (0.8 $\pm$ 4.7%) vs. (1.7 $\pm$ 4.4%) [mean difference –0.9% (95% CI –2.1–0.3), $P=0.15$ ]	Death: 12% vs. 11% ( $HR=1.10$ , 95% CI 0.57–2.14; $P=0.78$ ); rehospitalization for HF: 41% vs. 31% ( $HR=1.30$ , 95% CI 0.89–1.88; $P=0.17$ ); composite of death or rehospitalization for HF: 47% vs. 39% ( $HR=1.30$ , 95% CI 0.92–1.83; $P=0.14$ )

CHF congestive heart failure, LVEF left ventricular ejection fraction, HbA1c glycated hemoglobin, HF heart failure, T2DM type 2 diabetes mellitus, MI myocardial infarction, Afib atrial fibrillation, GLP-1RAs GLP-1 receptor agonists, HR hazard ratio, CI confidence interval

Though these findings were heterogeneous, there was no added benefit of liraglutide and its use therefore in clinical practice for this given population is not supported [95]. Lastly, it is important to look at how other anti-diabetic therapies affect HF to select an appropriate drug regimen for patients with excessive risk factors or established HF. The EMPA-REG OUTCOMES trial showed that empagliflozin, a SGLT-2i, markedly reduced the risk for HF hospitalization relative to the placebo ( $HR=0.65$ , 95% CI 0.50–0.85,  $P=0.002$ ) [96]. Though both liraglutide and empagliflozin reduce blood pressure, a risk factor to HF, the difference in HF hospitalization cannot be accounted for even when blood pressure is pre-controlled, and Scheen et al. [89] have postulated that this discrepancy in outcomes may be rooted in the diuretic function of SGLT-2i.

#### Effects of DPP-4i on HF

DPP-4 has been shown to directly increase factors that are predominant in HF. For example, DPP-4 cleaves BNP (1–32) into BNP (3–32), which is regularly detected in the plasma of patients with congestive HF [97].

Lourenço et al. [98, 99] sought to uncover an association between DPP-4 levels and the risk of mortality in patients who had HF with a reduced ejection fraction. There was an observed U-shape association between serum DPP-4 and mortality in patients with chronic systolic HF, and Lourenço et al. [98, 99] advised that DPP-4i will only be beneficial in instances where serum DPP-4 is extremely upregulated, 625 ng/ml or higher. Clinically, these findings should be considered when treating patients with DPP-4i, especially in those patients with HF.

Results from EXAMINE, SAVOR-TIMI53, and TECOS also shed some light on HF. EXAMINE showed a slight, but non-significant decrease in HF related hospitalization, while SAVOR-TIMI53 showed an increase in HF hospitalization with DPP-4i use. The TECOS trial showed no difference between the placebo and a sitagliptin group (Table 2) [47–49]. Pooled data from these three trials showed that rates of HF hospitalization were not significantly different between DPP-4i and placebo, suggesting that the effect may not be a class effect [100, 101]. Another meta-analysis including 43 trials ( $n=68,775$ ) and 12 observational studies ( $n=1,777,358$ ) concluded that the relative effect of DPP-4i as a class on HF in T2DM patients is uncertain. Recently completed CARMELINA and CAROLINA trials also suggested that linagliptin did not increase HF hospitalization compared to placebo or glimepiride [57, 58]. However, DPP-4i should be used with caution in T2DM patients with existing HF or risk factors [102].

#### Conclusions

The development of incretin-based treatments has helped improve the quality of life and the management of symptoms for patients inflicted with T2DM. Both GLP-1RAs and DPP-4i have proven to be effective in restoring overall glycemic control, lowering HbA1c and lipid levels, amongst other benefits. Cardiovascular safety of antidiabetic medications has received increasing attention since 2008 and here we summarize the recent updates from both clinical trials and preclinical experiments on the cardiovascular outcomes of this class of glucose-lowering drugs. Randomized controlled trials before the issue of CVOTs by the FDA in 2008 mainly focused on the efficacy of the blood glucose-lowering effects and a broad spectrum of adverse effects, with limited numbers of cardiovascular adverse events and relatively short follow-up duration. Thus, these trials are not thoroughly discussed in this review. Although some in-class heterogeneity has been observed, these CVOTs have shown that DPP-4i and GLP-RAs are safe relative to major cardiovascular outcomes. In addition, LEADER, SUSTAIN-6, HARMONY, PIONEER 6, REWIND, and AMPLITUDE-O found that GLP-1RAs had cardioprotective effects independent of their ability to lower blood glucose levels. The picture remains incomplete, however, when assessing the mechanism by which this is achieved and if these cardiovascular effects can be generalized for the entire class of drugs. With regards to specific outcomes such as HF, there has been heterogeneity in the results with both GLP-1RAs and DPP-4i. There have also been varying outcomes within classes depending on the etiology of the patient's HF. Therefore, more clinical trials utilizing a large generalizable T2DM patient population with less influence from baseline characteristics and longer follow-up durations are needed to help guide clinical decision-making and reduce the burden of T2DM while also promoting cardiovascular health.

#### Abbreviations

ADA: Adenosine deaminase; ADVANCE: Action in Diabetes and Vascular Disease: Preterax and Diamicon MR Controlled Evaluation; Afib: Atrial fibrillation; BNP: Brain natriuretic peptide; cAMP: Cyclic adenosine 3',5'-monophosphate; CI: Confidence interval; CKD: Chronic kidney disease; CVD: Cardiovascular disease; CVOTs: Cardiovascular outcome trials; DPP-4: Dipeptidyl peptidase-4; DPP-4i: DPP-4 inhibitor; eGFR: Estimated glomerular filtration rate; FDA: Food and Drug Administration; GAS: Interferon-gamma-activated sequence; GLP: Glucose-dependent insulinotropic polypeptide; GLP-1: Glucagon-like peptide-1; GLP-1R: GLP-1 receptor; GLP-1RAs: Glucagon-like peptide-1 receptor agonists; HbA1c: Glycated hemoglobin; HDL: High-density lipoprotein; HF: Heart failure; HNF-1 $\alpha$ : Hepatocyte nuclear factor-1 $\alpha$ ; HR: Hazard ratio; hs-CRP: High-sensitivity C-reactive protein; IL-12: Interleukin-12; IVUS: Intravascular ultrasound; LDL: Low-density lipoprotein; LVEF: Left ventricular ejection fraction; MACE: Major adverse cardiovascular events; MI: Myocardial infarction; MMPs: Matrix metalloproteases; PAI-1: Plasminogen activator inhibitor-1; PCI:

Percutaneous coronary intervention; PKA: Protein kinase A; PWV: Pulse wave velocity; SGLT-2i: Sodium/glucose cotransporter-2 inhibitors; STAT1 $\alpha$ : Signal transducer and activator of transcription 1 $\alpha$ ; T1DM: Type 1 diabetes mellitus; T2DM: Type 2 diabetes mellitus; TGF- $\beta$ : Transforming growth factor- $\beta$ ; TLR4: Toll-like receptor 4; TNF- $\alpha$ : Tumor necrosis factor- $\alpha$ ; TRIF: TIR-domain-containing adapter-inducing interferon- $\beta$ ; UKPDS: United Kingdom Prospective Diabetes Study; VLDL: Very low-density lipoprotein.

#### Acknowledgements

None.

#### Author contributions

MR performed literature search. MR, YYW, and JXZ drafted the manuscript. XQR and JXZ revised the manuscript. All authors have reviewed and agreed the submission. All authors read and approved the final manuscript.

#### Funding

This work was supported by the National Natural Science Foundation of China (81974254, 31870906, and 82170470).

#### Availability of data and materials

Not applicable.

#### Declarations

#### Ethics approval and consent to participate

Not applicable.

#### Consent for publication

Not applicable.

#### Competing interests

The authors declare that there is no conflict of interest in this manuscript.

#### Author details

<sup>1</sup>Tulane University School of Medicine, New Orleans, LA 70112, USA. <sup>2</sup>Department of Rheumatology and Immunology, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, 1095 Jiefang Ave, Wuhan 430032, China. <sup>3</sup>Department of Cardiovascular Medicine, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, 1095 Jiefang Ave, Wuhan 430032, China. <sup>4</sup>Institute of Allergy and Clinical Immunology, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan 430032, China.

Received: 6 January 2022 Accepted: 8 August 2022

Published online: 20 August 2022

#### References

- Rao Kondapally Seshasai S, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. *N Engl J Med*. 2011;364(9):829–41.
- Brown A, McArdle P, Taplin J, Unwin D, Unwin J, Deakin T, et al. Dietary strategies for remission of type 2 diabetes: a narrative review. *J Hum Nutr Diet*. 2021;35(1):165–78.
- Magkos F, Hjorth MF, Astrup A. Diet and exercise in the prevention and treatment of type 2 diabetes mellitus. *Nat Rev Endocrinol*. 2020;16(10):545–55.
- Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. *N Engl J Med*. 2008;359(15):1577–89.
- ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. *N Engl J Med*. 2008;358(24):2560–72.
- Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, et al. Effects of intensive glucose lowering in type 2 diabetes. *N Engl J Med*. 2008;358(24):2545–59.
- Low Wang CC, Everett BM, Burman KD, Wilson PWF. Cardiovascular safety trials for all new diabetes mellitus drugs? *Circulation*. 2019;139(14):1741–3.
- Ferro EG, Michos ED, Bhatt DL, Lincoff AM, Elshazly MB. New decade, new FDA guidance for diabetes drug development: lessons learned and future directions. *J Am Coll Cardiol*. 2020;76(21):2522–6.
- Waldrop G, Zhong J, Peters M, Goud A, Chen YH, Davis SN, et al. Incretin-based therapy in type 2 diabetes: an evidence based systematic review and meta-analysis. *J Diabetes Complic*. 2018;32(1):113–22.
- Lovshin JA, Drucker DJ. Incretin-based therapies for type 2 diabetes mellitus. *Nat Rev Endocrinol*. 2009;5(5):262–9.
- Müller TD, Finan B, Bloom SR, D'Alessio D, Drucker DJ, Flatt PR, et al. Glucagon-like peptide 1 (glp-1). *Mol Metab*. 2019;30:72–130.
- McLean BA, Wong CK, Campbell JE, Hodson DJ, Trapp S, Drucker DJ. Revisiting the complexity of GLP-1 action from sites of synthesis to receptor activation. *Endocr Rev*. 2021;42(2):101–32.
- Andersen A, Lund A, Knop FK, Vilsboll T. Glucagon-like peptide 1 in health and disease. *Nat Rev Endocrinol*. 2018;14(7):390–403.
- Larsen PJ, Holst JJ. Glucagon-related peptide 1 (GLP-1): hormone and neurotransmitter. *Regul Pept*. 2005;128(2):97–107.
- Zhou M, Mok MT, Sun H, Chan AW, Huang Y, Cheng AS, et al. The anti-diabetic drug exenatide, a glucagon-like peptide-1 receptor agonist, counteracts hepatocarcinogenesis through cAMP-PKA-EGFR-STAT3 axis. *Oncogene*. 2017;36(29):4135–49.
- Webb DL, Abrahamsson N, Sundbom M, Hellstrom PM. Bariatric surgery - time to replace with GLP-1? *Scand J Gastroenterol*. 2017;52(6–7):635–40.
- Waldrop G, Zhong J, Peters M, Rajagopalan S. Incretin-based therapy for diabetes: what a cardiologist needs to know. *J Am Coll Cardiol*. 2016;67(12):1488–96.
- Ast J, Arvaniti A, Fine NH, Nasteska D, Ashford FB, Stamatakis Z, et al. Super-resolution microscopy compatible fluorescent probes reveal endogenous glucagon-like peptide-1 receptor distribution and dynamics. *Nat Commun*. 2020;11(1):467.
- Hutch CR, Sandoval D. The role of GLP-1 in the metabolic success of bariatric surgery. *Endocrinology*. 2017;158(12):4139–51.
- Patel V, Joharapurkar A, Dhanesha N, Kshirsagar S, Patel K, Bahekar R, et al. Co-agonist of glucagon and GLP-1 reduces cholesterol and improves insulin sensitivity independent of its effect on appetite and body weight in diet-induced obese C57 mice. *Can J Physiol Pharmacol*. 2013;91(12):1009–15.
- Taher J, Baker CL, Cuizon C, Masoudpour H, Zhang R, Farr S, et al. GLP-1 receptor agonism ameliorates hepatic VLDL overproduction and de novo lipogenesis in insulin resistance. *Mol Metab*. 2014;3(9):823–33.
- Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide once weekly for the treatment of obesity. *N Engl J Med*. 2022;387(3):205–16.
- Hernández C, Bogdanov P, Corraliza L, Garcia-Ramirez M, Sola-Adell C, Arranz JA, et al. Topical administration of GLP-1 receptor agonists prevents retinal neurodegeneration in experimental diabetes. *Diabetes*. 2016;65(1):172–87.
- Steven S, Jurk K, Kopp M, Kroller-Schon S, Mikhed Y, Schwierczek K, et al. Glucagon-like peptide-1 receptor signalling reduces microvascular thrombosis, nitro-oxidative stress and platelet activation in endotoxaemic mice. *Br J Pharmacol*. 2017;174(12):1620–32.
- Wang D, Luo P, Wang Y, Li W, Wang C, Sun D, et al. Glucagon-like peptide-1 protects against cardiac microvascular injury in diabetes via a cAMP/PKA/Rho-dependent mechanism. *Diabetes*. 2013;62(5):1697–708.
- Berglund LM, Lyssenko V, Ladenvall C, Kotova O, Edsfieldt A, Pilgaard K, et al. Glucose-dependent insulinotropic polypeptide stimulates osteopontin expression in the vasculature via endothelin-1 and CREB. *Diabetes*. 2016;65(1):239–54.
- Scrocchi LA, Brown TJ, McClusky N, Brubaker PL, Auerbach AB, Joyner AL, et al. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. *Nat Med*. 1996;2(11):1254–8.
- Toft-Nielsen M, Madsbad S, Holst JJ. The effect of glucagon-like peptide I (GLP-I) on glucose elimination in healthy subjects depends on the pancreatic glucoregulatory hormones. *Diabetes*. 1996;45(5):552–6.

29. Chen BD, Zhao WC, Dong JD, Sima H. Expression of GLP-1R protein and its clinical role in intrahepatic cholangiocarcinoma tissues. *Mol Biol Rep*. 2014;41(7):4313–20.
30. Nauck MA, Siemsglöss J, Orskov C, Holst JJ. Release of glucagon-like peptide 1 (GLP-1 [7-36 amide]), gastric inhibitory polypeptide (GIP) and insulin in response to oral glucose after upper and lower intestinal resections. *Z Gastroenterol*. 1996;34(3):159–66.
31. Ussher JR, Drucker DJ. Cardiovascular biology of the incretin system. *Endocr Rev*. 2012;33(2):187–215.
32. Zhong J, Rao X, Deilulis J, Braunstein Z, Narula V, Hazey J, et al. A potential role for dendritic cell/macrophage-expressing dpp4 in obesity-induced visceral inflammation. *Diabetes*. 2013;62(1):149–57.
33. Gros R, You X, Baggio LL, Kabir MG, Sadi AM, Mungrue IN, et al. Cardiac function in mice lacking the glucagon-like peptide-1 receptor. *Endocrinology*. 2003;144(6):2242–52.
34. Zhong J, Gong Q, Goud A, Srinivasamaharaj S, Rajagopalan S. Recent advances in dipeptidyl-peptidase-4 inhibition therapy: lessons from the bench and clinical trials. *J Diabetes Res*. 2015;2015:606031.
35. Bengsch B, Seigel B, Flecken T, Wolanski J, Blum HE, Thimme R. Human Th17 cells express high levels of enzymatically active dipeptidylpeptidase IV (CD26). *J Immunol*. 2012;188(11):5438–47.
36. Rao X, Zhao S, Braunstein Z, Mao H, Razavi M, Duan L, et al. Oxidized ldl upregulates macrophage dpp4 expression via TLR4/TRIF/CD36 pathways. *EBioMedicine*. 2019;41:50–61.
37. Bruzese L, Rostain J-C, Née L, Condo J, Mottola G, Adjriou N, Mercier L, Berge-LeFranc J-L, Fromonot J, Kipsos N, Lucciano M, Durand-Gorde J-M, Jammes Y, Guieu R, Ruf J, Fenouillet E. Effect of hyperoxic and hyperbaric conditions on the adenosinergic pathway and CD26 expression in rat. *J Appl Physiol*. 2015;119(2):140–7. <https://doi.org/10.1152/jappphysiol.00223.2015>.
38. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. *Lancet*. 2002;359(9309):824–30.
39. Prasad-Reddy L, Isaacs D. A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond. *Drugs Context*. 2015;4:212283.
40. Gupta V. Glucagon-like peptide-1 analogues: an overview. *Indian J Endocrinol Metab*. 2013;17(3):413–21.
41. Saraiva FK, Sposito AC. Cardiovascular effects of glucagon-like peptide 1 (GLP-1) receptor agonists. *Cardiovasc Diabetol*. 2014;13:142.
42. Iacobellis G, Mohseni M, Bianco SD, Banga PK. Liraglutide causes large and rapid epicardial fat reduction. *Obesity*. 2017;25(2):311–6.
43. Helmstädter J, Keppeler K, Küster L, Munzel T, Daiber A, Steven S. Glucagon-like peptide-1 (GLP-1) receptor agonists and their cardiovascular benefits—the role of the GLP-1 receptor. *Br J Pharmacol*. 2022;179(4):659–76.
44. Kumar S, Mittal A, Mittal A. A review upon medicinal perspective and designing rationale of DPP-4 inhibitors. *Bioorg Med Chem*. 2021;46:116354.
45. Ahren B, Holst JJ, Mårtensson H, Balkan B. Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice. *Eur J Pharmacol*. 2000;404(1–2):239–45.
46. Chen XW, He ZX, Zhou ZW, Yang T, Zhang X, Yang YX, et al. Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus. *Clin Exp Pharmacol Physiol*. 2015;42(10):999–1024.
47. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. *N Engl J Med*. 2015;373(3):232–42.
48. White WB, Bakris GL, Bergenstal RM, Cannon CP, Cushman WC, Fleck P, Heller S, Mehta C, Nissen SE, Perez A, Wilson C, Zannad F. Examination of cardiovascular outcomes with alogliptin versus standard of care in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE). *Am Heart J*. 2011;162(4):620–626.e1. <https://doi.org/10.1016/j.ahj.2011.08.004>.
49. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. *N Engl J Med*. 2013;369(14):1317–26.
50. Oyama J, Murohara T, Kitakaze M, Ishizu T, Sato Y, Kitagawa K, et al. The effect of sitagliptin on carotid artery atherosclerosis in type 2 diabetes: the PROLOGUE randomized controlled trial. *PLoS Med*. 2016;13(6): e1002051.
51. de Boer SA, Heerspink HJL, Juárez Orozco LE, van Roon AM, Kamphuisen PW, Smit AJ, et al. Effect of linagliptin on pulse wave velocity in early type 2 diabetes: a randomized, double-blind, controlled 26-week trial (RELEASE). *Diabetes Obes Metab*. 2017;19(8):1147–54.
52. Nakamura T, Iwanaga Y, Miyaji Y, Nohara R, Ishimura T, Miyazaki S, et al. Cardiovascular efficacy of sitagliptin in patients with diabetes at high risk of cardiovascular disease: a 12-month follow-up. *Cardiovasc Diabetol*. 2016;15:54.
53. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. *N Engl J Med*. 2016;375(19):1834–44.
54. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. *N Engl J Med*. 2016;375(4):311–22.
55. Sattar N, Petrie MC, Zinman B, Januzzi Jr JL. Novel diabetes drugs and the cardiovascular specialist. *J Am Coll Cardiol*. 2017;69(21):2646–56.
56. Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Kober LV, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. *N Engl J Med*. 2015;373(23):2247–57.
57. Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N, et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. *JAMA*. 2019;321(1):69–79.
58. Rosenstock J, Kahn SE, Johansen OE, Zinman B, Espeland MA, Woerle HJ, et al. Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the carolina randomized clinical trial. *JAMA*. 2019;322(12):1155–66.
59. Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. *N Engl J Med*. 2017;377(13):1228–39.
60. Hernandez AF, Green JB, Janmohamed S, D'Agostino RB Sr, Granger CB, Jones NP, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. *Lancet*. 2018;392(10157):1519–29.
61. Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. *N Engl J Med*. 2019;381(9):841–51.
62. Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. *Lancet*. 2019;394(10193):121–30.
63. Gerstein HC, Sattar N, Rosenstock J, Ramasundarahettige C, Pratley R, Lopes RD, et al. Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. *N Engl J Med*. 2021;385(10):896–907.
64. Ferdinand KC, Botros FT, Atisso CM, Sager PT. Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events. *Cardiovasc Diabetol*. 2016;15:38.
65. Simó R, Guerci B, Scherthaner G, Gallwitz B, Rosas-Guzman J, Dotta F, et al. Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study. *Cardiovasc Diabetol*. 2015;14:116.
66. Courrèges JP, Vilsbøll T, Zdravkovic M, Le-Thi T, Krarup T, Schmitz O, et al. Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with type 2 diabetes. *Diabet Med*. 2008;25(9):1129–31.
67. Shih CJ, Chen HT, Kuo SC, Ou SM, Chen YT. Cardiovascular outcomes of dipeptidyl peptidase-4 inhibitors in elderly patients with type 2 diabetes: a nationwide study. *J Am Med Dir Assoc*. 2016;17(1):59–64.
68. Ryan D, Acosta A. GLP-1 receptor agonists: nonglycemic clinical effects in weight loss and beyond. *Obesity (Silver Spring)*. 2015;23(6):1119–29.
69. Giugliano D, Scappaticcio L, Longo M, Caruso P, Maiorino MI, Bellastella G, et al. GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs. *Cardiovasc Diabetol*. 2021;20(1):189.

70. Xia L, Shen T, Dong W, Su F, Wang J, Wang Q, et al. Comparative efficacy and safety of 8 GLP-1RAs in patients with type 2 diabetes: a network meta-analysis. *Diabetes Res Clin Pract.* 2021;177: 108904.
71. Longato E, Di Camillo B, Sparacino G, Tramontan L, Avogaro A, Fadini GP. Cardiovascular effectiveness of human-based vs. exendin-based glucagon like peptide-1 receptor agonists: a retrospective study in patients with type 2 diabetes. *Eur J Prev Cardiol.* 2021;28(1):22–9. <https://doi.org/10.1093/eurjpc/zwaa081>.
72. Gutzwiller JP, Tschopp S, Bock A, Zehnder CE, Huber AR, Kreyenbuehl M, et al. Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. *J Clin Endocrinol Metab.* 2004;89(6):3055–61.
73. McCormick LM, Heck PM, Ring LS, Kydd AC, Clarke SJ, Hoole SP, et al. Glucagon-like peptide-1 protects against ischemic left ventricular dysfunction during hyperglycemia in patients with coronary artery disease and type 2 diabetes mellitus. *Cardiovasc Diabetol.* 2015;14:102.
74. Gaspari T, Welungoda I, Widdop RE, Simpson RW, Dear AE. The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE(-/-) mouse model. *Diab Vasc Dis Res.* 2013;10(4):353–60.
75. Giugliano D, Longo M, Signoriello S, Maiorino MI, Solerte B, Chiodini P, et al. The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs. *Cardiovasc Diabetol.* 2022;21(1):42.
76. Chen JJ, Wu CY, Jenq CC, Lee TH, Tsai CY, Tu HT, et al. Association of glucagon-like peptide-1 receptor agonist vs dipeptidyl peptidase-4 inhibitor use with mortality among patients with type 2 diabetes and advanced chronic kidney disease. *JAMA Netw Open.* 2022;5(3):e221169.
77. Fang M, Wang D, Coresh J, Selvin E. Trends in Diabetes treatment and control in U.S. Adults, 1999–2018. *N Engl J Med.* 2021;384(23):2219–28. <https://doi.org/10.1056/NEJMsa2032271>.
78. Terasaki M, Nagashima M, Nohtomi K, Kohashi K, Tomoyasu M, Sinmura K, et al. Preventive effect of dipeptidyl peptidase-4 inhibitor on atherosclerosis is mainly attributable to incretin's actions in nondiabetic and diabetic apolipoprotein E-null mice. *PLoS ONE.* 2013;8(8):e70933.
79. Shah Z, Kampfrath T, Deiluiis JA, Zhong J, Pineda C, Ying Z, et al. Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis. *Circulation.* 2011;124(21):2338–49.
80. Zeng Y, Li C, Guan M, Zheng Z, Li J, Xu W, et al. The DPP-4 inhibitor sitagliptin attenuates the progress of atherosclerosis in apolipoprotein-E-knockout mice via AMPK- and MAPK-dependent mechanisms. *Cardiovasc Diabetol.* 2014;13:32.
81. Nozue T, Fukui K, Koyama Y, Fujii H, Kunishima T, Hikita H, et al. Effects of sitagliptin on coronary atherosclerosis in patients with type 2 diabetes: A serial integrated backscatter-intravascular ultrasound study. *Am J Cardiovasc Dis.* 2016;6(4):153–62.
82. Sun F, Wu S, Guo S, Yu K, Yang Z, Li L, et al. Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: a systematic review and network meta-analysis. *Diabetes Res Clin Pract.* 2015;110(1):26–37.
83. Avgerinos I, Michailidis T, Liakos A, Karagiannis T, Matthews DR, Tsapas A, et al. Oral semaglutide for type 2 diabetes: a systematic review and meta-analysis. *Diabetes Obes Metab.* 2020;22(3):335–45.
84. Sun F, Shanshan W, Wang J, Guo S, Chai S, Yang Z, Li L, Zhang Y, Ji L, Zhan S. Effect of glucagon-like peptide-1 receptor agonists on lipid profiles among type 2 diabetes: a systematic review and network meta-analysis. *Clin Ther.* 2015;37(1):225–241.e8. <https://doi.org/10.1016/j.clinthera.2014.11.008>.
85. Gejl M, Søndergaard HM, Stecher C, Bibby BM, Moller N, Botker HE, et al. Exenatide alters myocardial glucose transport and uptake depending on insulin resistance and increases myocardial blood flow in patients with type 2 diabetes. *J Clin Endocrinol Metab.* 2012;97(7):E1165–9.
86. Witteles RM, Keu KV, Quon A, Tavana H, Fowler MB. Dipeptidyl peptidase 4 inhibition increases myocardial glucose uptake in nonischemic cardiomyopathy. *J Card Fail.* 2012;18(10):804–9.
87. Ban K, Noyan-Ashraf MH, Hoefler J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. *Circulation.* 2008;117(18):2340–50.
88. Zhao T, Parikh P, Bhashyam S, Bolukoglu H, Poornima I, Shen YT, et al. Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts. *J Pharmacol Exp Ther.* 2006;317(3):1106–13.
89. Scheen AJ. GLP-1 receptor agonists and heart failure in diabetes. *Diabetes Metab.* 2017;43(Suppl 1):2S13.
90. Margulies KB, Hernandez AF, Redfield MM, Givertz MM, Oliveira GH, Cole R, et al. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. *JAMA.* 2016;316(5):500–8.
91. Jorsal A, Kistorp C, Holmager P, Tougaard RS, Nielsen R, Hanselmann A, et al. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial. *Eur J Heart Fail.* 2017;19(1):69–77.
92. Arturi F, Succuro E, Miceli S, Cloro C, Ruffo M, Maio R, et al. Liraglutide improves cardiac function in patients with type 2 diabetes and chronic heart failure. *Endocrine.* 2017;57(3):464–73.
93. Chen WR, Hu SY, Chen YD, Zhang Y, Qian G, Wang J, et al. Effects of liraglutide on left ventricular function in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. *Am Heart J.* 2015;170(5):845–54.
94. Huang M, Wei R, Wang Y, Su T, Li Q, Yang X, et al. Protective effect of glucagon-like peptide-1 agents on reperfusion injury for acute myocardial infarction: a meta-analysis of randomized controlled trials. *Ann Med.* 2017;49(7):552–61.
95. Liang B, Gu N. Liraglutide in the treatment of heart failure: insight from FIGHT and LIVE. *Cardiovasc Diabetol.* 2020;19(1):106.
96. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. *N Engl J Med.* 2015;373(22):2117–28.
97. Vanderheyden M, Bartunek J, Goethals M, Verstreken S, Lambeir AM, De Meester I, et al. Dipeptidyl-peptidase IV and B-type natriuretic peptide. From bench to bedside. *Clin Chem Lab Med.* 2009;47(3):248–52.
98. Lourenço P, Silva S, Cunha F, Pereira J, Ribeiro A, Silva N, et al. Dipeptidyl peptidase-IV in chronic heart failure with reduced ejection fraction. *Int J Cardiol.* 2017;241:249–54.
99. Lourenço P, Friões F, Silva N, Guimaraes JT, Bettencourt P. Dipeptidyl peptidase IV and mortality after an acute heart failure episode. *J Cardiovasc Pharmacol.* 2013;62(2):138–42.
100. Kankanala SR, Syed R, Gong Q, Ren B, Rao X, Zhong J. Cardiovascular safety of dipeptidyl peptidase-4 inhibitors: recent evidence on heart failure. *Am J Transl Res.* 2016;8(5):2450–8.
101. Verma S, Goldenberg RM, Bhatt DL, Farkouh ME, Quan A, Teoh H, et al. Dipeptidyl peptidase-4 inhibitors and the risk of heart failure: a systematic review and meta-analysis. *CMAJ Open.* 2017;5(1):E152–77.
102. Li L, Li S, Deng K, Liu J, Vandvik PO, Zhao P, et al. Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies. *BMJ.* 2016;352:i610.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more [biomedcentral.com/submissions](https://biomedcentral.com/submissions)

